HUP0301773A2 - Apomorfinszármazékok és alkalmazásaik - Google Patents
Apomorfinszármazékok és alkalmazásaikInfo
- Publication number
- HUP0301773A2 HUP0301773A2 HU0301773A HUP0301773A HUP0301773A2 HU P0301773 A2 HUP0301773 A2 HU P0301773A2 HU 0301773 A HU0301773 A HU 0301773A HU P0301773 A HUP0301773 A HU P0301773A HU P0301773 A2 HUP0301773 A2 HU P0301773A2
- Authority
- HU
- Hungary
- Prior art keywords
- apomorphine
- methods
- compounds
- po3h2
- so3h
- Prior art date
Links
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical class C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- MHPQCGZBAVXCGA-GFCCVEGCSA-N (6ar)-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol Chemical compound N1CCC2=CC=CC3=C2[C@H]1CC1=CC=C(O)C(O)=C13 MHPQCGZBAVXCGA-GFCCVEGCSA-N 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 229960004046 apomorphine Drugs 0.000 abstract 1
- -1 apomorphine derivative compounds Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
A találmány tárgyát apomorfinszármazék-vegyületek képezik, melyekszerkezete a következő képlettel jellemezhető: ahol n jelentése 1 és 4közötti egész szám, R1 jelentése: hidrogén-, alkil-, -PO3H2, -SO3Hvagy glükuronilcsoport, R2 jelentései egymástól függetlenülválaszthatóan hidrogén-, alkil-, -PO3H2, -SO3H vagy glükuronilcsoport; vagy a vegyületek gyógyászati szempontból elfogadható sója.Valamint a találmány további tárgyát a vegyületek nemi működészavarkezelésére szolgáló eljárásokban, valamint apomorfinos kezeléshatékonyságának fokozására történő alkalmazásai képezik. Előnyös atalálmány szerinti apomorfinszármazékok a norapomorfin. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19565000P | 2000-04-07 | 2000-04-07 | |
PCT/US2001/040393 WO2001076602A1 (en) | 2000-04-07 | 2001-03-29 | Apomorphine derivatives and methods for their use |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0301773A2 true HUP0301773A2 (hu) | 2003-09-29 |
HUP0301773A3 HUP0301773A3 (en) | 2006-02-28 |
Family
ID=22722192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0301773A HUP0301773A3 (en) | 2000-04-07 | 2001-03-29 | Apomorphine derivatives and methods for their use |
Country Status (18)
Country | Link |
---|---|
US (1) | US6506765B2 (hu) |
EP (1) | EP1284735A4 (hu) |
JP (1) | JP2003532640A (hu) |
KR (1) | KR20030036157A (hu) |
CN (1) | CN1471395A (hu) |
AU (1) | AU2001255818A1 (hu) |
BG (1) | BG107217A (hu) |
BR (1) | BR0109515A (hu) |
CA (1) | CA2405419A1 (hu) |
CZ (1) | CZ20023637A3 (hu) |
HU (1) | HUP0301773A3 (hu) |
IL (1) | IL151614A0 (hu) |
MX (1) | MXPA02009904A (hu) |
NO (1) | NO20024806D0 (hu) |
PL (1) | PL361672A1 (hu) |
SK (1) | SK15772002A3 (hu) |
WO (1) | WO2001076602A1 (hu) |
ZA (1) | ZA200207489B (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
SE0102036D0 (sv) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
BR0308567A (pt) * | 2002-03-19 | 2007-01-09 | Michael Holick | derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos |
WO2004069167A2 (en) * | 2003-01-31 | 2004-08-19 | Nastech Pharmaceutical Company Inc. | Method and compositions for treating male infertility |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
EP1613323A1 (en) * | 2003-04-14 | 2006-01-11 | Vectura Limited | Pharmaceutical compositions comprising apomorhine for pulmonary inhalation |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
ZA200803087B (en) | 2005-10-12 | 2009-11-25 | Unimed Pharmaceuticals Llc | Improved testosterone gel and method of use |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
TWI816716B (zh) | 2017-11-24 | 2023-10-01 | 丹麥商H 朗德貝克公司 | 用於治療帕金森病之新兒茶酚胺前驅藥 |
US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
AU6428894A (en) | 1993-03-26 | 1994-10-24 | Franciscus W.H.M. Merkus | Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine |
EP0978282B1 (en) | 1994-04-22 | 2005-12-14 | Pentech Pharmaceuticals, Inc. | Sublingual composition containing apomorphine for diagnosing functional impotence |
US5562917A (en) | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
US5888534A (en) | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
PT914097E (pt) | 1996-03-12 | 2002-06-28 | Alza Corp | Composicao e forma de dosagem compreendendo antagonista de opioide |
GB9700878D0 (en) | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
US5925629A (en) * | 1997-10-28 | 1999-07-20 | Vivus, Incorporated | Transurethral administration of androgenic agents for the treatment of erectile dysfunction |
AU751182B2 (en) | 1997-12-02 | 2002-08-08 | Archimedes Development Limited | Compositions for nasal administration |
US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
CA2334550A1 (en) * | 1998-06-22 | 1999-12-29 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
IT1299566B1 (it) * | 1998-07-17 | 2000-03-16 | Ifi Istituto Farmacoterapico I | Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina |
US5994363A (en) | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
MXPA01011480A (es) * | 1999-05-13 | 2002-06-04 | Unihart Corp | Composiciones farmaceuticas que comprenden apocodeina y/o sus derivados. |
-
2001
- 2001-03-29 CN CNA01815168XA patent/CN1471395A/zh active Pending
- 2001-03-29 IL IL15161401A patent/IL151614A0/xx unknown
- 2001-03-29 AU AU2001255818A patent/AU2001255818A1/en not_active Abandoned
- 2001-03-29 WO PCT/US2001/040393 patent/WO2001076602A1/en not_active Application Discontinuation
- 2001-03-29 CA CA002405419A patent/CA2405419A1/en not_active Abandoned
- 2001-03-29 MX MXPA02009904A patent/MXPA02009904A/es unknown
- 2001-03-29 EP EP01929027A patent/EP1284735A4/en not_active Withdrawn
- 2001-03-29 HU HU0301773A patent/HUP0301773A3/hu unknown
- 2001-03-29 US US09/821,236 patent/US6506765B2/en not_active Expired - Fee Related
- 2001-03-29 JP JP2001574119A patent/JP2003532640A/ja not_active Withdrawn
- 2001-03-29 PL PL01361672A patent/PL361672A1/xx not_active Application Discontinuation
- 2001-03-29 SK SK1577-2002A patent/SK15772002A3/sk not_active Application Discontinuation
- 2001-03-29 KR KR1020027013436A patent/KR20030036157A/ko not_active Application Discontinuation
- 2001-03-29 BR BR0109515-3A patent/BR0109515A/pt not_active IP Right Cessation
- 2001-03-29 CZ CZ20023637A patent/CZ20023637A3/cs unknown
-
2002
- 2002-09-18 ZA ZA200207489A patent/ZA200207489B/xx unknown
- 2002-10-04 NO NO20024806A patent/NO20024806D0/no not_active Application Discontinuation
- 2002-10-24 BG BG107217A patent/BG107217A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
BG107217A (bg) | 2003-05-30 |
AU2001255818A1 (en) | 2001-10-23 |
EP1284735A4 (en) | 2006-01-11 |
NO20024806D0 (no) | 2002-10-04 |
KR20030036157A (ko) | 2003-05-09 |
HUP0301773A3 (en) | 2006-02-28 |
US6506765B2 (en) | 2003-01-14 |
CA2405419A1 (en) | 2001-10-18 |
SK15772002A3 (sk) | 2003-09-11 |
CZ20023637A3 (cs) | 2003-02-12 |
MXPA02009904A (es) | 2004-09-06 |
PL361672A1 (en) | 2004-10-04 |
ZA200207489B (en) | 2003-12-18 |
JP2003532640A (ja) | 2003-11-05 |
BR0109515A (pt) | 2004-08-10 |
WO2001076602A1 (en) | 2001-10-18 |
IL151614A0 (en) | 2003-04-10 |
EP1284735A1 (en) | 2003-02-26 |
US20020002176A1 (en) | 2002-01-03 |
CN1471395A (zh) | 2004-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0301773A2 (hu) | Apomorfinszármazékok és alkalmazásaik | |
ATE437872T1 (de) | Proteinkinaseinhibitoren | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
CY1105579T1 (el) | Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες | |
AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
CY1109558T1 (el) | Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων | |
CY1108808T1 (el) | Ενωσεις μοτιλιδης | |
MXPA04004370A (es) | Derivados policiclicos de guanina inhibidores de fosfodiesterasa v. | |
HUP9802678A2 (hu) | Biciklusos aminszármazékok és ezeket tartalmazó PGD2 antagonista hatású készítmények | |
MXPA06001494A (es) | Compuestos de piramidina condensados como inhibidores de canales ionicos gatillados por tension. | |
SG151260A1 (en) | 5-substituted-2-phenylamino-benzamides as mek inhibitors | |
GB0413087D0 (en) | Therapeutic compounds | |
YU75603A (sh) | Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja | |
BG108180A (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
NO20033959L (no) | Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon | |
ATE272617T1 (de) | Sulfonamid-derivate | |
UA83821C2 (ru) | Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли | |
UA86873C2 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
EA200100297A1 (ru) | Моногидрат гидробромида элетриптана | |
BRPI0418375A (pt) | derivados de diaza-espiropiperidina | |
PE20040975A1 (es) | Derivados de aril- y heteroarilmorfolina | |
DE60227113D1 (de) | Kondensierte camptothecine als antitumormittel | |
UY26111A1 (es) | Derivados de ciclobuten-3, 4-diona, su preparación y su aplicación en terapéutica | |
MXPA04000615A (es) | Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. | |
TH76785B (th) | สารประกอบลาพาโคนชนิดใหม่และวิธีใช้มัน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |